Bank Julius Baer & Co’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Bank Julius Baer & Co’s Portfolio PGNX Stock Details PGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-795	Closed	-$3K	–	767
2020 Q1	$3K	Buy	+795	New	+$3.42K	﹤0.01%	622

Other funds holding PGNX

ECM

Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Daiwa Securities Group Tokyo, Japan $51.1B AUM 35.55% 1-Year Est. Return

Bank Julius Baer & Co's PGNX Position: Q2 2020 in Review

Bank Julius Baer & Co sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 795 shares — an estimated $3K sold.

Bank Julius Baer & Co first reported a position in PGNX in Q1 2020 and held it in 1 quarter. The position peaked at $3K in Q1 2020. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

Bank Julius Baer & Co reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
Bank Julius Baer & Co sold 795 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $3K.
Bank Julius Baer & Co first reported a position in Progenics Pharmaceuticals Inc in Q1 2020 and held it in 1 quarter.
Bank Julius Baer & Co's Progenics Pharmaceuticals Inc position peaked at $3K in Q1 2020.
3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Bank Julius Baer & Co's 13F filing for Q2 2020, filed 10 Aug 2020.